Evaluation of UCPVax Vaccine +/- Pembrolizumab Combined With Standard Treatment as Adjuvant Therapy in Patients With Unmethylated MGMT Glioblastoma
Evaluation of UCPVax Vaccine +/- Pembrolizumab Combined With Standard Treatment as Adjuvant Therapy in Patients With Unmethylated MGMT Glioblastoma
Not yet recruiting · NCT07347210 · Registry updated 2026-01-16Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Evaluation of UCPVax Vaccine +/- Pembrolizumab Combined With Standard Treatment as Adjuvant Therapy in Patients With Unmethylated MGMT Glioblastoma | Primary Glioblastoma | Not yet recruiting | Phase 2 | 2026-01-16 | NCT07347210 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Centre Hospitalier Universitaire de Besancon | 73 |
| Merck Sharp & Dohme LLC | 650 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Centre Georges François Leclerc | Dijon | France | 35 |
| CHU de Besançon | Besançon | France | 26 |
| CHU La Timone | Marseille | France | 8 |
| Hôpital Saint-Louis - APHP | Paris | France | 1 |